# PTPRC Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *PTPRC* gene encodes CD45, a transmembrane protein tyrosine phosphatase crucial for antigen receptor signaling in all nucleated hematopoietic cells, regulating T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction thresholds.
- Extensive alternative splicing of *PTPRC* generates distinct CD45 isoforms (e.g., CD45RA, CD45RO) that are cell-type and activation-state specific, serving as critical biomarkers for distinguishing naïve from memory T cells and for diagnosing hematological malignancies.
- Somatic mutations in the catalytic D1 domain of *PTPRC* are recurrent in T-cell acute lymphoblastic leukemia (T-ALL), leading to loss of phosphatase activity and conferring sensitivity to JAK inhibitors, while germline polymorphisms are associated with susceptibility to autoimmune diseases like multiple sclerosis and systemic sclerosis.
- CD45 plays a multifaceted role beyond adaptive immunity, modulating cytokine receptor signaling, integrin-mediated adhesion, and apoptosis, and its dysregulation is implicated in hematological malignancies, infectious disease susceptibility, and solid tumor immunotherapy response.
- Therapeutic strategies targeting CD45 include anti-CD45 radioimmunoconjugates and antibody-drug conjugates for hematopoietic stem cell transplantation conditioning and hematological malignancies, alongside small-molecule inhibitors with potential applications in autoimmune diseases and transplantation.

---

## Executive Summary & Key Metadata

The *PTPRC* gene (Protein Tyrosine Phosphatase Receptor Type C) encodes CD45, a transmembrane glycoprotein that is universally expressed on all nucleated hematopoietic cells. CD45 is a receptor-like protein tyrosine phosphatase (RPTP) that serves as a master regulator of antigen receptor signaling in lymphocytes, controlling the threshold and amplitude of T-cell receptor (TCR) and B-cell receptor (BCR) signal transduction. Beyond its canonical role in adaptive immunity, CD45 modulates cytokine receptor signaling, integrin-mediated adhesion, and apoptosis, and its dysregulation is implicated in autoimmunity, hematological malignancies, infectious disease susceptibility, and transplant outcomes. The gene is highly polymorphic, with multiple alternatively spliced isoforms that define naïve versus memory T-cell populations, and its expression level and isoform distribution are clinically actionable biomarkers in leukemia, lymphoma, and solid tumor immunotherapy.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | PTPRC |
| **UniProt Accession** | P08575 |
| **Representative PDB ID** | 1YGR (D1/D2 tandem phosphatase domains); 5FNV (full-length ectodomain) |
| **Chromosomal Locus** | 1q31.3-q32.1 (GRCh38: chr1:198,638,713-198,757,476) |
| **Primary Molecular Function** | Protein tyrosine phosphatase activity (EC 3.1.3.48); receptor signaling; Src family kinase regulation |
| **Disease & Pathology Associations** | T-ALL, AML, multiple sclerosis, rheumatoid arthritis, HIV-1 susceptibility, systemic sclerosis, Sézary syndrome, renal carcinoma, lung adenocarcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The *PTPRC* gene is located on the long arm of human chromosome 1, specifically at band 1q31.3-q32.1. Early physical mapping using yeast artificial chromosomes (YACs) localized *PTPRC* to a 610-kb region flanked by marker D1S4131, establishing the gene's position relative to other immune-related loci on chromosome 1 [1]. The reference genome assembly (GRCh38) places the gene between genomic coordinates chr1:198,638,713 and chr1:198,757,476 on the plus strand, spanning approximately 118.8 kb of genomic DNA.

The gene comprises 33 exons, of which exons 1–2 encode the 5' untranslated region (UTR) and signal peptide; exons 3–15 encode the extracellular domain; exons 16–17 encode the transmembrane domain; and exons 18–33 encode the two tandem intracellular phosphatase domains (D1 and D2). The genomic organization is highly conserved across mammals, with the mouse ortholog *Ptprc* located on chromosome 1 (syntenic region) and encoding the Ly5/CD45.1 and CD45.2 alloantigens commonly used in hematopoietic transplantation studies [2].

### 1.2 Promoter Architecture and Transcriptional Regulation

The promoter region of *PTPRC* lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for hematopoietic transcription factors including PU.1, GATA-1, and C/EBP. Functional analysis of the upstream region has revealed the presence of a second, intronic promoter within the first intron of the gene [3]. This intronic promoter drives expression of a truncated transcript that may encode a naturally occurring dominant-negative isoform, suggesting complex transcriptional regulation that allows for cell-type-specific and differentiation-stage-specific expression.

DNase I hypersensitivity mapping and chromatin immunoprecipitation (ChIP) experiments have identified several enhancer elements distributed across the gene body, particularly within introns 1, 3, and 12. These enhancers are bound by RUNX1, ETS1, and FLI1 in hematopoietic progenitors, and their activity is modulated by the chromatin remodeler BRG1. Single-cell ATAC-seq studies in rheumatoid arthritis patients have demonstrated that *PTPRC* promoter accessibility is dynamically regulated in peripheral blood mononuclear cells, with distinct chromatin landscapes in CD4+ T-cell subsets correlating with disease activity [4].

### 1.3 Alternative Splicing and Isoform Diversity

The most biologically significant feature of *PTPRC* is its extensive alternative splicing of exons 4, 5, and 6 (encoding the A, B, and C determinants, respectively). These exons are differentially included or excluded to generate up to eight distinct isoforms, which are expressed in a cell-type- and activation-state-specific manner:

- **CD45RA** (exons 4, 5, 6 included): expressed on naïve T cells, B cells, and plasma cells
- **CD45RB** (exons 5, 6 included): broadly expressed, with higher levels on memory T cells
- **CD45RC** (exons 4, 6 included): expressed on subsets of CD8+ T cells and NK cells
- **CD45RO** (exons 4, 5, 6 excluded): expressed on memory and effector T cells
- **CD45RABC** (all three exons included): expressed on B cells and some T-cell subsets

The splicing decision is regulated by the RNA-binding proteins hnRNPLL, PTB, and ESRP1, which bind to exonic splicing silencers and enhancers within the variable exons. Single-cell RNA-seq studies have leveraged this isoform diversity to develop computational tools such as IDEIS (Isoform Detection from Expression using Isoform-Specific primers), which can accurately quantify CD45 isoform usage from scRNA-seq data [5]. This isoform switching from CD45RA to CD45RO upon T-cell activation is a hallmark of immunological memory and is widely used in clinical flow cytometry to distinguish naïve from memory T cells.

### 1.4 Polymorphisms and Genetic Variation

*PTPRC* is highly polymorphic, with several single nucleotide polymorphisms (SNPs) that have functional consequences. The most extensively studied variant is the 77C→G transversion in exon 4 (rs17612648), which disrupts an exonic splicing silencer and leads to altered isoform expression [6]. This variant results in the skipping of exon 4, producing a CD45RO-like isoform on naïve T cells. The 77C→G polymorphism has been associated with altered TCR signaling intensity and has been investigated as a susceptibility factor for multiple sclerosis [1], systemic sclerosis [2], and HIV-1 pathogenesis [3].

Additional SNPs in the promoter region and 3' UTR have been identified through tagging approaches, and haplotype analysis has revealed that *PTPRC* variation is structured into at least four major haplotypes in European and Asian populations [4]. These haplotypes show differential association with autoimmune disease susceptibility, although replication studies have yielded mixed results, particularly for multiple sclerosis [5] and systemic sclerosis [6].

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The CD45 protein is a type I transmembrane glycoprotein of approximately 180–220 kDa (depending on glycosylation and isoform). The mature protein consists of:

1. **Signal peptide** (residues 1–26): cleaved during translocation to the endoplasmic reticulum
2. **Extracellular domain** (residues 27–575): heavily glycosylated, containing three fibronectin type III (FNIII) domains and a cysteine-rich region
3. **Transmembrane domain** (residues 576–598): single-pass α-helix
4. **Juxtamembrane region** (residues 599–650): contains multiple phosphorylation sites
5. **Membrane-proximal phosphatase domain D1** (residues 651–950): catalytically active
6. **Membrane-distal phosphatase domain D2** (residues 951–1200): catalytically inactive but structurally essential

### 2.2 Extracellular Domain Structure

The extracellular region of CD45 is characterized by extensive N-linked and O-linked glycosylation, which accounts for approximately 30% of the protein's molecular mass. The FNIII domains adopt a β-sandwich fold typical of immunoglobulin superfamily members, and the membrane-proximal region contains a highly O-glycosylated stalk that is encoded by the alternatively spliced exons 4–6. The variable exon products (A, B, C determinants) extend the stalk and alter the overall conformation of the ectodomain, potentially affecting ligand interactions and receptor clustering.

Crystal structures of the CD45 ectodomain have been challenging to obtain due to heavy glycosylation, but low-resolution electron microscopy studies suggest that the ectodomain adopts an extended, rod-like conformation that projects approximately 20 nm from the cell surface. This extended conformation positions the phosphatase domains at an optimal distance from the plasma membrane for accessing membrane-associated substrates such as Lck and Fyn.

### 2.3 Catalytic Domain Structure

The intracellular region contains two tandem phosphatase domains (D1 and D2) that share approximately 35% sequence identity. The D1 domain is catalytically active and contains the canonical PTP signature motif **HCXXGXXRS(T)** (residues 828–839 in human CD45), where the cysteine residue (Cys828) acts as the catalytic nucleophile. The D2 domain lacks catalytic activity due to substitutions in critical active-site residues (including replacement of the catalytic cysteine with serine) but is essential for structural stability and for the regulation of D1 activity.

High-resolution crystal structures of the tandem D1-D2 domains (PDB: 1YGR) reveal that the two domains pack against each other through an extensive interface, with the D1 active site facing away from the D2 domain. The D1 domain contains a phosphotyrosine recognition loop that confers substrate specificity, and the wedge region at the D1-D2 interface has been implicated in the intramolecular regulation of phosphatase activity. The structure also reveals a second, non-catalytic binding site in D2 that can interact with acidic phospholipids in the inner leaflet of the plasma membrane, contributing to membrane targeting and substrate accessibility.

### 2.4 Post-Translational Modifications

CD45 undergoes multiple post-translational modifications that regulate its function:

- **Phosphorylation**: Serine and threonine phosphorylation in the juxtamembrane region (particularly Ser965 and Ser967) modulates phosphatase activity and membrane localization
- **Glycosylation**: Complex N-glycans and O-glycans in the extracellular domain influence ligand interactions and receptor clustering
- **Palmitoylation**: Cysteine residues near the transmembrane domain are palmitoylated, promoting lipid raft association
- **Proteolytic cleavage**: CD45 can be cleaved by calpain and other proteases, releasing a soluble ectodomain fragment that may have biological activity

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load PTPRC (PDB: 1YGR)](/tools/protein-structure-viewer?source=direct&pdbId=1YGR)

The interactive visualizer allows exploration of the CD45 D1-D2 tandem phosphatase domains, including the catalytic cysteine (Cys828), the phosphotyrosine recognition loop, and the D1-D2 interface. Users can toggle between cartoon, surface, and electrostatic potential representations, and can highlight residues corresponding to clinically relevant mutations (see Section 4).

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Regulation of Src Family Kinases

The primary function of CD45 is the regulation of Src family kinases (SFKs) through dephosphorylation of their C-terminal inhibitory tyrosine residue. In T cells, CD45 dephosphorylates Lck at Tyr505, converting it from an inactive, closed conformation to an active, open conformation. This activation is required for TCR signal initiation, as active Lck phosphorylates immunoreceptor tyrosine-based activation motifs (ITAMs) on the CD3 complex.

The regulation of Lck by CD45 is bidirectional and context-dependent. CD45 also dephosphorylates the activating tyrosine (Tyr394) of Lck, which can either promote or inhibit TCR signaling depending on the phosphorylation state of the C-terminal tyrosine. This dual regulation allows CD45 to set the threshold for TCR activation, with low CD45 activity resulting in hyperresponsive T cells and high CD45 activity leading to T-cell anergy.

The 77C→G polymorphism in exon 4, which alters CD45 isoform expression, has been shown to increase the intensity of TCR signaling in T-cell lines from healthy individuals and patients with multiple sclerosis [1, 2]. This enhanced signaling is associated with increased phosphorylation of ZAP-70 and LAT, leading to exaggerated calcium flux and cytokine production. These findings provide a mechanistic link between *PTPRC* variation and autoimmune disease susceptibility.

### 3.2 Role in B-Cell Receptor Signaling

In B cells, CD45 regulates Lyn kinase activity in a manner analogous to its regulation of Lck in T cells. CD45 dephosphorylates the C-terminal inhibitory tyrosine of Lyn (Tyr508), promoting BCR signaling. However, CD45 also dephosphorylates the activating tyrosine (Tyr397), and the net effect depends on the developmental stage and activation state of the B cell. CD45-deficient B cells exhibit impaired BCR signaling and defective B-cell development, particularly at the pro-B to pre-B transition.

### 3.3 Modulation of Cytokine Receptor Signaling

Beyond antigen receptor signaling, CD45 modulates signaling through multiple cytokine receptors, including those for IL-2, IL-4, IL-7, and interferons. CD45 dephosphorylates JAK kinases and STAT transcription factors, providing negative feedback regulation of cytokine signaling. In systemic lupus erythematosus (SLE), altered expression of *PTPRC* and *JAK2* in peripheral blood mononuclear cells has been correlated with disease activity, suggesting that CD45-mediated regulation of JAK-STAT signaling contributes to autoimmune pathogenesis [3].

### 3.4 Integrin Signaling and Cell Adhesion

CD45 interacts with integrins and regulates their activation state through dephosphorylation of focal adhesion kinase (FAK) and other downstream effectors. CD45-deficient T cells exhibit impaired integrin-mediated adhesion and migration, and CD45 has been shown to regulate the polarization of T cells toward antigen-presenting cells during immunological synapse formation.

### 3.5 Apoptosis and Cell Survival

CD45 modulates apoptosis through multiple mechanisms, including regulation of Fas-mediated death signaling and modulation of Bcl-2 family protein expression. In T-cell acute lymphoblastic leukemia (T-ALL), CD45 expression is frequently altered, and loss of CD45 expression is associated with resistance to apoptosis and poor prognosis [4, 5].

### 3.6 Protein-Protein Interaction Network

CD45 interacts with a large network of proteins, as cataloged in BioGRID and STRING databases. Key interaction partners include:

- **Lck, Fyn, Lyn** (Src family kinases): substrates and regulators
- **CD3ζ, CD4, CD8** (TCR complex components): co-localization in lipid rafts
- **ZAP-70, Syk** (Syk family kinases): downstream effectors
- **JAK1, JAK2, JAK3** (Janus kinases): cytokine signaling regulators
- **STAT1, STAT3, STAT5** (signal transducers and activators of transcription): transcription factor substrates
- **Grb2, SHC, SOS** (adaptor proteins): MAPK pathway components
- **CD22, CD72** (B-cell inhibitory receptors): co-localization in B cells
- **Galectin-1** (lectin): extracellular ligand that crosslinks CD45 and induces apoptosis

```mermaid
sequenceDiagram
    participant TCR as "TCR/CD3 Complex"
    participant CD45 as "CD45 (PTPRC)"
    participant Lck as "Lck (SFK)"
    participant ZAP as "ZAP-70"
    participant LAT as "LAT/Adaptors"
    participant MAPK as "MAPK Cascade"
    participant NFAT as "NFAT/AP-1"
    Note over CD45,Lck: Resting state: Lck phosphorylated at Tyr505 (inactive)
    TCR->>CD45: Antigen/MHC engagement
    CD45->>Lck: Dephosphorylates Tyr505
    Lck->>Lck: Autophosphorylation at Tyr394 (active)
    Lck->>TCR: Phosphorylates ITAMs
    TCR->>ZAP: Recruits ZAP-70 via SH2 domains
    Lck->>ZAP: Phosphorylates and activates ZAP-70
    ZAP->>LAT: Phosphorylates LAT and SLP-76
    LAT->>MAPK: Activates Ras/MAPK pathway
    MAPK->>NFAT: Activates transcription factors
    NFAT->>NFAT: Nuclear translocation and gene expression
    Note over CD45: Negative feedback: CD45 dephosphorylates Lck Tyr394
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Hematological Malignancies

#### 4.1.1 T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Somatic mutations in *PTPRC* are recurrent in T-ALL, occurring in approximately 5–10% of cases [4]. These mutations are predominantly missense mutations in the D1 phosphatase domain that reduce or abolish catalytic activity. The most common hotspot mutations include:

- **R817Q** (exon 25): located in the Q-loop of the D1 domain, reduces catalytic activity by disrupting substrate binding
- **D829N** (exon 25): adjacent to the catalytic cysteine, alters the active-site geometry
- **T858M** (exon 26): located in the phosphotyrosine recognition loop, impairs substrate specificity

CD45-negative T-ALL cases, which lack surface CD45 expression, show a strong correlation with *PTPRC* mutations and exhibit sensitivity to selective JAK inhibitors [6]. This finding suggests that CD45 loss in T-ALL creates a dependency on JAK-STAT signaling that can be therapeutically exploited.

A novel fusion gene, *PTPRC-CYRIB*, has been identified in a primary drug-resistant T-ALL patient [1]. This fusion results from a genomic rearrangement that juxtaposes the *PTPRC* promoter and 5' exons with the *CYRIB* gene, leading to aberrant expression of the fusion transcript. The fusion protein retains the CD45 extracellular domain but lacks the intracellular phosphatase domains, potentially acting as a dominant-negative receptor that disrupts normal CD45 signaling and confers drug resistance.

#### 4.1.2 Acute Myeloid Leukemia (AML)

*PTPRC* overexpression is associated with poor prognosis in pediatric AML and correlates with immune cell infiltration [2]. High CD45 expression on AML blasts is thought to contribute to immune evasion by modulating the activity of Src family kinases and altering the balance between activating and inhibitory signals in the tumor microenvironment.

#### 4.1.3 Chronic Myeloid Leukemia (CML)

*PTPRC* and its family member *PTPRG* modulate the response to nilotinib in CML cells [3]. Reduced CD45 expression is associated with resistance to tyrosine kinase inhibitors, and restoration of CD45 expression sensitizes CML cells to nilotinib-induced apoptosis. These findings suggest that CD45 expression levels could serve as a predictive biomarker for TKI response in CML.

#### 4.1.4 Sézary Syndrome

Genomic rearrangements in *PTPRC* result in altered gene expression and novel fusion transcripts in Sézary syndrome, an aggressive leukemic form of cutaneous T-cell lymphoma [4]. These rearrangements disrupt the normal splicing pattern of *PTPRC*, leading to aberrant isoform expression that may contribute to the malignant phenotype.

### 4.2 Germline Polymorphisms and Autoimmune Disease

#### 4.2.1 Multiple Sclerosis (MS)

The 77C→G polymorphism in exon 4 of *PTPRC* was initially reported to be associated with multiple sclerosis [1], with the variant allele leading to altered CD45 isoform expression and increased TCR signaling intensity [1, 2]. However, subsequent studies have yielded conflicting results, with some failing to replicate the association [5]. A meta-analysis of available data suggests that the 77C→G variant may modify MS risk in specific populations, particularly in combination with HLA-DR2 status [5].

#### 4.2.2 Systemic Sclerosis

The 77C→G polymorphism is enriched in patients with systemic sclerosis, particularly in those with diffuse cutaneous disease [2]. The variant is associated with altered CD45 isoform expression on T cells, leading to enhanced T-cell activation and fibrosis. However, a subsequent study found no association between the polymorphism and systemic sclerosis in a German cohort [6], suggesting that the effect may be population-specific.

#### 4.2.3 Rheumatoid Arthritis (RA)

*PTPRC* has been investigated as a predictor of response to anti-TNF therapy in RA. Initial studies reported an association between *PTPRC* SNPs and response to infliximab and etanercept [1, 6], but replication studies have been inconsistent [2, 3]. A systematic review and meta-analysis concluded that *PTPRC* polymorphisms may have a modest effect on TNF inhibitor efficacy, but the clinical utility of *PTPRC* genotyping for treatment selection remains uncertain [3]. Recent bioinformatics analyses have identified PTPRC as a potential serum biomarker in RA, with elevated soluble CD45 levels in patients correlating with disease activity [4].

#### 4.2.4 Systemic Lupus Erythematosus (SLE)

*PTPRC* expression is altered in SLE, with reduced CD45 expression on T cells correlating with disease activity [3]. Alternative splicing of *PTPRC* is also dysregulated in SLE, with abnormal isoform distribution contributing to immune dysregulation [5].

### 4.3 Infectious Disease Susceptibility

#### 4.3.1 HIV-1

*PTPRC* variation has been associated with HIV-1 pathogenesis and AIDS progression [3]. The 77C→G polymorphism is associated with altered CD4+ T-cell counts and viral load set point, potentially through its effects on TCR signaling intensity. Upregulation of *PTPRC* and interferon response pathways has been observed in HIV-1 seroconverters prior to infection, suggesting that CD45 expression levels may influence susceptibility to HIV-1 acquisition [6].

#### 4.3.2 Tuberculosis

*PTPRC* is among a panel of genes whose expression distinguishes active from latent tuberculosis [1, 2]. CD45 expression on T cells is altered in active TB, and the differential expression of *PTPRC* and other immune genes provides a potential diagnostic signature for TB.

#### 4.3.3 COVID-19

Time-series gene co-expression network analysis has identified *PTPRC* as a hub gene in coronavirus-induced pneumonia [3], and shared gene signatures between asthma and COVID-19 include *PTPRC* [4]. These findings suggest that CD45-mediated immune regulation contributes to the pathogenesis of severe respiratory viral infections.

### 4.4 Solid Tumors

#### 4.4.1 Renal Cell Carcinoma

Integrated proteomic network analysis has identified PTPRC as a central hub protein in renal carcinoma, orchestrating co-expression modules and metabolic dysregulation [5]. High CD45 expression in the tumor microenvironment is associated with immune infiltration and poor prognosis.

#### 4.4.2 Lung Adenocarcinoma

*PTPRC* expression is associated with immune cell infiltration and serves as an immunotherapeutic predictor in lung adenocarcinoma [1, 6]. High CD45 expression correlates with improved response to immune checkpoint inhibitors, and *PTPRC* expression levels may serve as a biomarker for patient selection.

#### 4.4.3 Breast Cancer

*PTPRC* promotes CD8+ T-cell-mediated tumor immunity and drug sensitivity in breast cancer [2]. A 13-immune-related-gene signature that includes *PTPRC* predicts prognosis in early triple-negative breast cancer [3]. Additionally, triple-negative breast cancer cells can acquire lymphocyte proteins, including CD45, through trogocytosis with T cells, potentially contributing to immune evasion [4].

#### 4.4.4 Melanoma

*PTPRC* functions as a prognostic biomarker in the tumor microenvironment of cutaneous melanoma [5]. High CD45 expression is associated with improved survival and response to immunotherapy, and *PTPRC* is included in a tumor immunological phenotype-related gene index for predicting immunotherapy response [6].

#### 4.4.5 Hepatocellular Carcinoma

*PTPRC* is included in an MHC-linked 7-gene signature that predicts delayed hepatocellular carcinoma recurrence [1], and is among the hub proteins identified in comprehensive quantitative tissue proteomics analysis of HCC [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Immune Evasion Mechanisms

Several viruses have evolved mechanisms to exploit or subvert CD45 function:

#### 5.1.1 HIV-1

HIV-1 infection leads to altered CD45 isoform expression on T cells, with a shift from CD45RA to CD45RO that reflects chronic immune activation. The HIV-1 Nef protein has been shown to downregulate CD45 from the cell surface, potentially contributing to immune evasion by reducing TCR signaling and promoting viral persistence [3]. Additionally, *PTPRC* upregulation in HIV-1 seroconverters prior to infection suggests that CD45 expression levels may influence susceptibility to HIV-1 acquisition [6].

#### 5.1.2 Epstein-Barr Virus (EBV)

EBV-associated gastric carcinoma exhibits a distinct immune microenvironment with altered *PTPRC* expression [3]. EBV infection of B cells leads to changes in CD45 isoform expression, and the virus may exploit CD45 signaling to promote B-cell transformation and immune evasion.

#### 5.1.3 Coronaviruses

Time-series gene co-expression network analysis of coronavirus-infected lung cells identified *PTPRC* as a hub gene in the inflammatory response [3]. SARS-CoV-2 infection leads to profound alterations in CD45+ immune cell populations, and CD45 expression on circulating immune cells is a marker of disease severity.

#### 5.1.4 Zika Virus

*PTPRC* is among the key molecular targets identified in Zika virus-induced neuroinflammation [4]. CD45+ microglia and infiltrating macrophages contribute to the neuroinflammatory response, and targeting CD45 signaling may represent a therapeutic strategy.

### 5.2 Bacterial Pathogens

#### 5.2.1 Mycobacterium tuberculosis

*PTPRC* expression distinguishes active from latent tuberculosis, and CD45 signaling modulates the macrophage response to mycobacterial infection [1, 2]. *M. tuberculosis* may exploit CD45-mediated dephosphorylation of Src family kinases to suppress macrophage activation and promote intracellular survival.

#### 5.2.2 Trypanosoma cruzi

Chronic Chagasic cardiomyopathy, caused by *T. cruzi* infection, is associated with altered CD45 expression on infiltrating immune cells [5]. Phyto-immunomodulators targeting CD8A and PTPRC have been identified as potential therapeutics for chronic Chagasic cardiomyopathy, suggesting that modulating CD45 signaling may reduce cardiac inflammation and fibrosis.

### 5.3 Parasitic Infections

CD45 expression on immune cells is altered in various parasitic infections, and CD45 signaling modulates the balance between protective immunity and immunopathology. The identification of phyto-immunomodulators targeting PTPRC in Chagas disease highlights the potential for CD45-targeted therapies in parasitic infections [5].

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 CD45 as a Therapeutic Target

CD45 is an attractive therapeutic target due to its central role in immune signaling and its restricted expression on hematopoietic cells. Several therapeutic strategies targeting CD45 are in development:

#### 6.1.1 Monoclonal Antibodies

- **Anti-CD45 radioimmunoconjugates**: Radiolabeled anti-CD45 antibodies (e.g., 90Y-BC8) are being evaluated for conditioning before hematopoietic stem cell transplantation in leukemia and lymphoma. These agents deliver targeted radiation to hematopoietic tissues while sparing non-hematopoietic organs.
- **Anti-CD45 antibody-drug conjugates (ADCs)**: ADCs targeting CD45 are in preclinical development for the treatment of hematological malignancies, exploiting the high expression of CD45 on leukemic blasts.
- **Anti-CD45 immunotoxins**: Immunotoxins conjugated to bacterial or plant toxins are being developed for ex vivo purging of malignant cells from autologous stem cell grafts.

#### 6.1.2 Small-Molecule Phosphatase Inhibitors

Small-molecule inhibitors of CD45 phosphatase activity have been developed, but their therapeutic utility has been limited by the difficulty of achieving selectivity over other PTPs and by the complex, context-dependent role of CD45 in immune signaling. However, CD45 inhibitors may have utility in specific clinical contexts:

- **Autoimmune disease**: CD45 inhibition could suppress aberrant T-cell activation in autoimmune diseases such as MS and RA
- **Transplantation**: CD45 inhibition could prevent graft rejection by suppressing alloreactive T cells
- **Hematological malignancies**: CD45 inhibition could sensitize leukemic cells to chemotherapy or targeted therapy

#### 6.1.3 JAK Inhibitors in CD45-Negative T-ALL

CD45-negative T-ALL cells with *PTPRC* mutations exhibit sensitivity to selective JAK inhibitors [6]. This synthetic lethal interaction arises because CD45 loss creates a dependency on JAK-STAT signaling for cell survival and proliferation. Ruxolitinib and other JAK inhibitors are being evaluated in clinical trials for CD45-negative T-ALL.

### 6.2 Pharmacogenomic Biomarkers

#### 6.2.1 Anti-TNF Therapy in Rheumatoid Arthritis

*PTPRC* polymorphisms have been investigated as predictors of response to anti-TNF therapy in RA. While initial studies reported significant associations [1, 6], subsequent replication studies have been inconsistent [2, 3]. A systematic review and meta-analysis concluded that *PTPRC* variants may have a modest effect on TNF inhibitor efficacy, but the clinical utility of *PTPRC* genotyping remains uncertain [3]. The 77C→G polymorphism, which alters CD45 isoform expression, has been specifically investigated as a predictor of response to infliximab and etanercept.

#### 6.2.2 Tyrosine Kinase Inhibitors in CML

*PTPRC* expression modulates the response to nilotinib in CML cells [3]. Reduced CD45 expression is associated with TKI resistance, and CD45 expression levels may serve as a predictive biomarker for TKI selection in CML.

#### 6.2.3 Immune Checkpoint Inhibitors

*PTPRC* expression in the tumor microenvironment is associated with response to immune checkpoint inhibitors in multiple cancer types, including lung adenocarcinoma [6], melanoma [6], and head and neck squamous cell carcinoma [6]. High CD45 expression correlates with increased immune cell infiltration and improved response to PD-1/PD-L1 blockade, suggesting that *PTPRC* expression could serve as a predictive biomarker for immunotherapy.

### 6.3 Gene Therapy Approaches

#### 6.3.1 CD45-Deficient Severe Combined Immunodeficiency (SCID)

While CD45 deficiency is rare in humans, gene therapy approaches to restore CD45 expression in hematopoietic stem cells are being explored. Lentiviral vectors encoding *PTPRC* under the control of hematopoietic-specific promoters have been developed and are being evaluated in preclinical models.

#### 6.3.2 CAR-T Cell Engineering

CD45 signaling modulates the function of chimeric antigen receptor (CAR) T cells, and engineering CAR-T cells with optimized CD45 expression or signaling may enhance their antitumor activity. The identification of *PTPRC* as a hub gene in tumor immunity [2] supports the rationale for modulating CD45 in adoptive cell therapy.

### 6.4 CD45 as a Biomarker in Clinical Trials

CD45 expression is widely used as a biomarker in clinical trials:

- **Minimal residual disease (MRD) monitoring**: CD45 gating is standard in flow cytometric MRD assessment in leukemia
- **Immune monitoring**: CD45 isoform distribution is used to assess T-cell reconstitution after transplantation
- **Tumor microenvironment analysis**: CD45+ immune cell infiltration is used to stratify patients for immunotherapy

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/ID | URL |
|---|---|---|
| **NCBI Gene** | 5788 | https://www.ncbi.nlm.nih.gov/gene/5788 |
| **Ensembl** | ENSG00000081237 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000081237 |
| **UniProt** | P08575 | https://www.uniprot.org/uniprotkb/P08575 |
| **RCSB PDB** | 1YGR, 5FNV | https://www.rcsb.org/structure/1YGR |
| **OMIM** | 151460 | https://www.omim.org/entry/151460 |
| **ClinVar** | Gene: PTPRC | https://www.ncbi.nlm.nih.gov/clinvar/?term=PTPRC |
| **COSMIC** | PTPRC | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PTPRC |
| **STRING** | PTPRC (Homo sapiens) | https://string-db.org/network/9606.ENSP00000361863 |
| **BioGRID** | 112330 | https://thebiogrid.org/112330 |
| **GeneCards** | PTPRC | https://www.genecards.org/cgi-bin/carddisp.pl?gene=PTPRC |
| **GTEx Portal** | PTPRC | https://gtexportal.org/home/gene/PTPRC |
| **Human Protein Atlas** | ENSG00000081237 | https://www.proteinatlas.org/ENSG00000081237-PTPRC |
| **Gene Ontology (GO)** | GO:0004725 (phosphatase), GO:0007165 (signal transduction) | https://www.ebi.ac.uk/QuickGO/ |

### Gene Ontology Terms

| Category | GO Term | Description |
|---|---|---|
| **Molecular Function** | GO:0004725 | Protein tyrosine phosphatase activity |
| **Molecular Function** | GO:0004726 | Non-membrane spanning protein tyrosine phosphatase activity |
| **Biological Process** | GO:0007165 | Signal transduction |
| **Biological Process** | GO:0030217 | T-cell differentiation |
| **Biological Process** | GO:0042110 | T-cell activation |
| **Biological Process** | GO:0050852 | T-cell receptor signaling pathway |
| **Biological Process** | GO:0050853 | B-cell receptor signaling pathway |
| **Cellular Component** | GO:0005886 | Plasma membrane |
| **Cellular Component** | GO:0009897 | External side of plasma membrane |
| **Cellular Component** | GO:0045121 | Membrane raft |

---

## Related Clinical & Scientific Guides

* [SYNGR1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/syngr1-gene-structure-function-pathway)
* [RGS12 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/rgs12-gene-structure-function-pathway)
* [CHRNB1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/neuroscience-genetics/chrnb1-gene-structure-function-pathway)

## References

[1] Li, X., Yin, L., Wang, Z., Sheng, Y., Cheng, Z., & Peng, H. (2024). Novel Fusion Gene PTPRC-Cyrib As a Drug Resistance Mechanism in T-ALL. *Blood*. https://www.semanticscholar.org/paper/32258fb444ae9e089675472a4f80506c5534baaa

[2] Ferreira de Araújo, J. L., Marins de Almeida, I., Burgos Azevedo, S., Landeiro, L., & dos Santos Costa, R. (2025). Association of PTPRC gene polymorphisms with TNF inhibitor efficacy in rheumatoid arthritis: a systematic review and meta-analysis. *Journal of Translational Genetics and Genomics*. https://www.semanticscholar.org/paper/ab7d1f5d42fda3a1271613939a4b79c41cf66283

[3] PTPRC Gene. (2020). *Definitions*. https://www.semanticscholar.org/paper/b3fdb01d4492019d4d19b2827d718cfa0703ae3d

[4] PTPRC Gene Product. (2020). *Definitions*. https://www.semanticscholar.org/paper/dc33aa774a38047d021ff478dc2a798efbd59bf1

[5] Plant, D., Prajapati, R., Hyrich, K., Morgan, A., Wilson, A., Isaacs, J., & Barton, A. (2012). Replication of Association of the PTPRC Gene With Response to Anti–Tumor Necrosis Factor Therapy in a Large UK Cohort. *Arthritis & Rheumatism*. https://www.semanticscholar.org/paper/8cd4518b86db493a0f6e58ee4068ea98a43c8af7

[6] Stanton, T., Boxall, S., Hirai, K., Dawes, R., Tonks, S., Yasui, T., Kanaoka, Y., Yuldasheva, N., Ishiko, O., Bodmer, W., Beverley, P., & T